Skip to main content

Etiological and Biological Aspects of Cigarette Smoking in Rheumatoid Arthritis

Buy Article:

$63.00 plus tax (Refund Policy)

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by the chronic inflammation of the synovium, which develops to joint destruction. Quite interestingly RA has not been present in the old world until 17 century. Tobacco has come from the new world, and epidemiological studies revealed cigarette smoking as a major risk factor for the disease. However, the mechanism how cigarette smoking contributes to RA has been largely unknown. It has been demonstrated that polycyclic aromatic hydrocarbons, constituents of cigarette smoke, and cigarette smoke extracts are able to induce proinflammatory cytokines from RA patient-derived fibroblast-like synoviocytes. Recent studies also suggest an important role of Th17 in RA and contribution of aryl hydrocarbon receptor to the induction and development of Th17 and RA. These new findings lead to uncovering the basis for the etiological role of cigarette smoking in the disease.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: AhR; Cigarette smoking; Th17; cytokine; inflammation; rheumatoid arthritis; synovial cell

Document Type: Research Article

Publication date: 01 December 2009

More about this publication?
  • Inflammation & Allergy - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in inflammation and allergy e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in inflammation and allergy. As the discovery, identification, characterization and validation of novel human drug targets for anti-inflammation and allergy drug discovery continues to grow, this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more